In Re Cyclobenzaprine Hydrochloride Extended-Release Capsule Patent Litigation

Opinion

NOTE: ThiS order is n0nprecedentia1. United States Court of AppeaIs for the Federal Circuit IN RE CYCLOBENZAPRINE HYDROCHLORIDE EXTENDED-RELEASE CAPSULE PATENT LITIGATION EURAND, INC., CEPHALON, INC., AND ANESTA AG, Plaintiffs-Appellees, V. MYLAN PHARMACEUTICALS INC. AND MYLAN INC., Defen,dants-Appellants. 2011-1399 Appeal from the United States District C0urt for the District of DelaWare in case n0. 09-MD-2118, Judge Sue L. R0binS0n. ON MOTION Bef0re GAJARSA, Circuit Judge. 0 R D E R

EURAND V. MYLAN 2 Mylan Pharmaceuticals Inc. et al. (Mylan) move for expedited briefing and argument Upon consideration thereof IT ls 0RDERED THA'r: The motion to expedite is granted in part. Mylan’s initial brief is due within seven days of docketing of the appeal Eurand, Inc. et al.’s brief is due within. ten days from the date of service of Mylan’s brief. Mylan’s reply brief and the joint appendix are due within three days from the date of service of Eurand’s response brief The case will be placed on the next available oral argument calendar after the brieHng is completed. FoR THE CoUR'r l‘lAY 31 2011 /s/ J an Horbal_v Date J an Horbalj Clerk cc: Jarnes H. Wallace, Jr., Esq. William J. Marsden, Jr., Esq. § l.8. 02UEF PBB FOR S19 TH F D LClRCUlT HAT 31 2011 .IANiURBAl.¥ GLEl¥l